Stock Analysis

Peter Anastasiou Is The Executive Vice Chairman of Immuron Limited (ASX:IMC) And They Just Sold Some Of Their Shares

ASX:IMC
Source: Shutterstock

We wouldn't blame Immuron Limited ( ASX:IMC ) shareholders if they were a little worried about the fact that Peter Anastasiou, the Executive Vice Chairman recently netted about AU$890k selling shares at an average price of AU$0.31. That diminished their direct individual holding by 100%.

Check out our latest analysis for Immuron

Advertisement

Immuron Insider Transactions Over The Last Year

In fact, the recent sale by Peter Anastasiou was the biggest sale of Immuron shares made by an insider individual in the last twelve months, according to our records. That means that an insider was selling shares at slightly below the current price (AU$0.33). We generally consider it a negative if insiders have been selling, especially if they did so below the current price, because it implies that they considered a lower price to be reasonable. However, while insider selling is sometimes discouraging, it's only a weak signal. It is worth noting that this sale was 100% of Peter Anastasiou's direct individual holding, however, he may own additional stock through indirectly through other vehicles such as trusts and corporate structures.

In the last year Immuron insiders didn't buy any company stock. The chart below shows insider transactions (by individuals) over the last year. If you click on the chart, you can see all the individual transactions, including the share price, individual, and the date!

ASX:IMC Recent Insider Trading June 20th 2020
ASX:IMC Recent Insider Trading June 20th 2020

If you like to buy stocks that insiders are buying, rather than selling, then you might just love this free list of companies. (Hint: insiders have been buying them).

Insider Ownership of Immuron

I like to look at how many shares insiders own in a company, to help inform my view of how aligned they are with insiders. I reckon it's a good sign if insiders own a significant number of shares in the company. From our data, it seems that Immuron insiders own 12% of the company, worth about AU$6.8m. However, it's possible that insiders might have an indirect interest through a more complex structure. Whilst better than nothing, we don't see these holdings as being overly large in value terms.

So What Does This Data Suggest About Immuron Insiders?

Insiders haven't bought Immuron stock in the last three months, but there was some selling. Looking to the last twelve months, our data doesn't show any insider buying. Insiders own relatively few shares in the company, and when you consider the sales, we're not particularly excited about the stock. So we're not rushing to buy, to say the least. While we like knowing what's going on with the insider's ownership and transactions, we make sure to also consider what risks are facing a stock before making any investment decision. Every company has risks, and we've spotted 6 warning signs for Immuron (of which 2 are concerning!) you should know about.

Of course, you might find a fantastic investment by looking elsewhere. So take a peek at this free list of interesting companies.

For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body. We currently account for open market transactions and private dispositions, but not derivative transactions.

Love or hate this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com .

This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Thank you for reading.

About ASX:IMC

Immuron

A biopharmaceutical company, engages in the research, development, and commercialization of polyclonal antibodies in Australia, the United States, and Canada.

Flawless balance sheet and fair value.

Advertisement